The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody shot to protect infants up to one year ...

Patients in the study had tumors with a genetic defect known as deficient DNA mismatch repair, or dMMR. About 15% of colon ...

Other innovations in booth food: Novartis had charcuterie (guys, you know preserved meat is carcinogenic, right?) and Eli Lilly had a salad bar. The lettuce did not have a Lilly logo.

Both cars’ custom paint jobs will prominently feature Zero and AstraZeneca’s logos. Meanwhile, Zero’s logo will also appear on another pair of cars—No. 17 and No. 77, driven by Conor Daly ...

AstraZeneca (AZN) CEO Pascal Soriot is not overly concerned about the threat of tariffs by the Trump administration on pharmaceuticals and said a more favorable corporate tax credit could motivate ...

Revenues came in at $13.59 billion, missing Wall Street's estimates of $13.76 billion. In this photo illustration, the AstraZeneca logo is displayed on a smartphone screen with a stock market chart in ...

The positive recommendation from NICE for osimertinib was based on results from the ADAURA Phase III trial. In which, adjuvant treatment (after surgery) with osimertinib in patients with stage II ...

Thought LeaderMina MakarSenior Vice President, Global CVRMAstraZeneca NewsMedical spoke with Mina Makar, Senior Vice President of Global CVRM at AstraZeneca, about groundbreaking research in Heart ...

Sept 26 (Reuters) - AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm's AI model of the immune system to make certain cancer drug trials more ...

AstraZeneca’s booming oncology business has won over cancer patient groups. Having languished down the leaderboard in the past, the drugmaker vaulted (PDF) over many rivals in PatientView’s ...

AstraZeneca is adding to the explosion of interest in radiopharmaceuticals, inking a $2 billion buyout to meld Fusion Pharmaceuticals with its cancer unit. Fusion’s pipeline is led by a PSMA ...